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Suppression by pravastatin, an inhibitor of p21 ras
isoprenylation, of hepatocarcinogenesis induced by
N-nitrosomorpholine in Sprague-Dawley rats
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Summary The effect of pravastatin, an inhibitor of p21 ras isoprenylation, on hepatocarcinogenesis induced by N-nitrosomorpholine and on
p2l s isoprenylation were investigated in male Sprague-Dawley rats. Rats received i.p. injections of pravastatin (10 and 20 mg kg-1 body
weight) every other day and, from the beginning of the experiment, were given drinking water containing N-nitrosomorpholine for 8 weeks.
Vesible white nodules and hepatic lesions staining positively for gamma-glutamyl transpeptidase orglutathione-S-transferase, placental type,
were examined macroscopically or histochemically. In week 15, pravastatin at both dosages significantly reduced the incidence, number and
volume of visible white nodules. Quantitative histological analysis also showed that prolonged administration of pravastatin at both dosages
resulted in significant reductions in the number and percentage area of hepatic lesions positive for gamma-glutamyl transpeptidase and
glutathione-S-transferase, placental type. Administration of pravastatin also significantly decreased the amount of membrane-associated
p21 ras in the tumour and the labelling index of neoplastic nodules and increased the apoptoic indices of neoplastic nodules. These findings
indicate that pravastatin suppresses hepatocarcinogenesis and suggest that this effect might be related to pravastatin's inhibition of p21 ras
isoprenylation and its subsequent inhibition of cell proliferation and induction of apoptosis in neoplastic lesions.
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Activating mutations of the K-ras gene have been detected in
human hepatocellular carcinomas (Gu et al. 1986). Recently we
found H-ras mutation of hepatic neoplastic lesions induced by
N-nitrosomorpholine (Baba et al, 1997). The ras-encoded protein
p21 is localized at the plasma membrane, where it plays a key role
in signal transduction (Grand and Owen, 1991; Egan and
Weinberg, 1993; McCormick, 1993). The membrane association
and function ofp21 are dependent on a series ofpost-translational
processing steps, including isoprenylation (Sinensky et al, 1990);
the biosynthesis of polyisoprenoids involved in p2lras processing
is part of the mevalonate pathway of cholesterol synthesis.
Pravastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme that
regulates the biosynthesis ofcholesterol (Kawata et al, 1994). This
drug can inhibit p21ras isoprenylation and membrane localization
(Kawata et al, 1994). Narisawa et al (1994) found that pravastatin
suppresses development of colon cancers induced by 1,2-
dimethylhydrazine in female ICR mice. However, there are no
reports of its effect on experimental hepatocarcinogenesis.
Therefore, in the present work, we examined the effect of
pravastatin on the development of hepatic lesions induced by
N-nitrosomorpholine (NNM) in Sprague-Dawley rats.
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MATERIALS AND METHODS
Animals
Sixty young (6-week-old) male Sprague-Dawley rats were
purchased from Japan SLC (Shizuoka, Japan). The animals were
housed in suspended, wire-bottomed metal cages in animal quar-
ters with controlled temperature (21-22°C), humidity (30-50%)
and light (12-h cycle), and had free access to regular chow pellets
(Nihon-Nosan, Yokohama, Japan).
Experimental design
After the acclimation for 1 week, animals were randomly divided
into three groups of 20 rats each and treated as follows: group 1,
the control group, was given 0.9% sodium chloride solution only
i.p. every other day until the end of the experiment in week 15.
From the beginning of the experiment, animals were also given
drinking water containing 175 mg 1-1 of NNM (Sigma, St Louis,
MO, USA) for 8 weeks. The NNM was dissolved in distilled water
at a concentration of 50 g l-1 and stored in a cool place. The stock
solution was diluted to 175 mg 1-1 with tap water just before use
and supplied to rats from the bottles with renewal every other day.
From week 9 onwards, rats were given normal tap wateronly, until
the end of the experiment. From the beginning of the experiment,
groups 2 and 3 received i.p. injections of pravastatin (a gift from
Sankyo, Tokyo, Japan) at doses of 10 mg kg-' and 20 mg kg-' body
weight, respectively, in 0.9% sodium chloride solution every other
day until the end ofthe experiment in week 15. The rats in groups
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2 and 3 were also given NNM for 8 weeks in the same way as
group 1. Injections were given i.p. in a volume of 2 ml kg-' body
weight, between 1400 and 1500 hours.
Macroscopical, histological and histochemical
observations of hepatic lesions
In week 15, the non-fasted rats were all killed by ether anaesthesia
between 1400 and 1500 hours. On the horizontally sliced liver
specimens, white nodule formation was observed macroscopically.
The counts of white nodules per rat were measured by slicing the
entire liver at close intervals and recording the number of liver
tumour per liver. Then 2- or 3-mm-thick liver sections obtained
from the left and middle lobes were fixed in cold acetone (0-4'C)
for6 h and embedded inparaffin. Serial sections of3 ,um thickness
were stained with haematoxylin and eosin, gamma-glutamyl
transpeptidase (GGT), using the procedure of Ruttenberg et al
(1969), or glutathione-S-transferase, placental type (GST-P),
using the immunohistochemical peroxidase-antiperoxidase (PAP)
method described by Stemnberg et al (1970) using anti-rat GST-P
rabbit serum (Bio Prep Medlabs, Stillogan, Ireland).
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Figure 1 Incidence, number and volume of visible white nodules in groups
1 (sodium chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at
20 mg kg-') at week 15. Bars show s.e. Difference compared with group 1
was statistically significant: *P< 0.05, **P< 0.02, ***P < 0.01, ****P< 0.001
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Histological typing of liver tumours
According to the criteria of Institute of Laboratory Animal
Resources (1980), liver tumours induced in rats were classified
into three types. (1) Cellular alteration foci - in this lesion, the
plates of hepatocytes that compose it merge imperceptibly with
those of the surrounding liver tissue. There is no compression of
the surrounding liver tissue, and the lesion is nevertheless sharply
demarcated by the appearance and staining reaction of its cells.
Within the lesions are slight inconstant variations in the size ofthe
cells and the size, morphology and staining reaction oftheirnuclei
and nucleoli. In this series, however, this type of liver tumour
could not be detected. (2) Neoplastic nodules - this lesion consists
predominantly of acidophilic or basophilic cells or a mixture
thereof. The cells vary in size. The nucleus may be enlarged and
hyperchromatic; the nucleolus is prominent. The hepatocytes
composing the nodule are arranged in thin cords. An important
feature, in addition to the architectural distortions, is the sharp
demarcation of the periphery of the nodule or portions of it from
the surrounding liver tissue. (3) Hepatocellular carcinoma - this
lesion replicates the cellular and architectural patterns ofthe broad
liver cords of hepatic-like cells that alternate with endothelium-
lined sinusoid-like blood vascular channels. The neoplastic cells
exhibit varying degrees of cytological alterations. In this study,
neoplastic nodules and hepatocellular carcinomas are called
neoplastic lesions.
Measurement of enzyme-altered hepatic lesions
Serial sections were scored for GST-P-positive and GGT-positive
lesions without knowledge oftheir groups oforigin. Only hepatic
lesions 0.2 mm or more in greatest diameter in the plane of tran-
section were counted, as reproducible evaluation of lesions less
than 0.2 mm in diameter was impossible. The transectional area of
lesions in the plane oftissue section and the area ofthe entire liver
section were measured with an LA-500 Personal Image Analyzer
System (Pias, Tokyo, Japan). In calculating the two-dimensional
focus stereology, the area of liver occupied by hepatocellular
carcinomas was subtracted.
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Figure 2 Number and size of GST-P-positive lesions and GGT-positive
lesions in the liver of groups 1 (sodium chloride), 2 (pravastatin at
10 mg kg-') and 3 (pravastatin at 20 mg kg-') at week 15. Bars show s.e.
Difference compared with group 1 was statistically significant: *P< 0.05,
**P < 0.02, ***P< 0.01
Measurement of labelling index
The labelling indices of the neoplastic nodules and the
surrounding liver were examined in week 15. The labelling index
was measured with an immunohistochemical analysis kit for
assaying bromodeoxyuridine (BrdU) incorporation (Gratzner,
1982; Morstyn et al, 1983) (Becton-Dickinson, Mountain View,
CA, USA). For this purpose, five unstarved rats in each group of
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Figure 3 Microphotographs of GGT-positive lesions and GST-P-positive lesions in the liver of groups 1 (sodium chloride) and 3 (pravastatin at 20 mg kg-1) at
week 15. GGT-positive lesions (C) and GST-P-positive lesions (D) in a rat treated with pravastatin at 20 mg kg-' body weight were fewer and smaller than GGT-
positive lesions (A) and GST-P-positive lesions (B) in a control rat. Bar = 1 mm
the original 20 rats received 0.9% sodium chloride solution (group
1) or 10 or 20 mg kg' body weight ofpravastatin (groups 2 and 3).
One hour later, rats received an i.p. injection of 20 mg kg-' body
weight of BrdU, and another 1 h later they were killed with ether.
Sections obtained from the left liver lobe were promptly fixed in
70% ethanol (0-4°C) for 4 h and embedded in paraffin. Serial
sections of 3-jm thickness were immersed in 2 N hydrochloric
acid solution for 30 min at room temperature and then in 0.1 M
sodium borate to neutralize the acid. Sections were then stained
with anti-BrdU monoclonal antibody (diluted 1:25) for 2 h at room
temperature, washed, stained with biotin-conjugated horse anti-
mouse antibody (diluted 1:200) for 30 min, and stained with
avidin-biotin-peroxidase complex for 30 min. The reaction product
was located with 3,3' -diaminobenzidine tetrahydrochloride. Cells
containing BrdU were identified by the presence of dark pigment
over their nuclei. For determining the labelling index, the number
of BrdU-labelled cells were counted among 500 cells in the
surrounding liver and in neoplastic nodules. The labelling index
was expressed as the percentage of labelled cells among the cells
examined.
Measurement of apoptotic index
The apoptotic indices of the neoplastic nodules were examined at
week 15. The apoptotic index was measured with an in situ apoptotic
detection kit (Oncor, Gaithersburg, MD, USA) for assaying apop-
totic cells by direct immunoperoxidase detection of digoxigenin-
labelled genomic DNA in 5-jm sections of fixed tissue obtained
from the liver of rats (Schmitz et al, 1991). Digoxigenin-labelled
cells among 500 cells in the neoplastic lesions were counted. The
apoptotic index was expressed as the percentage of labelled cells
among the cells examined.
Western blotting of ras protein
Western blotting of ras protein in the white nodules was performed
by the method of Ura et al (1994). Several microscopically visible
white nodules were excised from the livers of rats. Tumour
specimens were homogenized with lysis buffer containing 50 mm
N-[2-hydroxyethyl]piperazine-N'-2-ethane-sulphonic acid (HEPES;
pH 7.4), 250 mm sodium chloride, 1 mm EDTA, 0.5% NP-40 and
1 mM phenylmethylsulphonyl fluoride (PMSF). The homogenate
was centrifuged at 12 000 g for 30 min at 4°C, and the resulting
supematants were frozen at-800C until assay. The protein concen-
tration of lysates was estimated with BCA Protein Assay Reagent
(Pierce, Rockford, IL, USA). After being boiled for 3 min, the
lysate proteins were separated by 13% sodium dodecylsulphate-
polyacrylamide gel (SDS-PAGE). The gel was transblotted to a
nitrocellulose membrane (Hybond-ECL, Amersham, LittleChalfont,
Buckinghamshire, UK) in Tris glycine buffer (125 mM, 960 mM
glycine and 20% methanol) for 40 min at 170 mA using a semidry
Western blotting apparatus (Nihon Eido, Tokyo, Japan). The blotted
membrane was immersed in 5% skimmed milk to block non-
specific binding sites and then washed with phosphate-buffered
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Figure 4 Microphotographs of hepatic neoplastic lesions in a rat treated
with NNM alone at week 15. Each of serial sections was stained with
haematoxylin and eosin (A), GGT (B) and GST-P (C). Lesion No. 1 was
positive for both GST-P and GGT. Lesion no. 2 was positive for GGT but not
positive for GST-P. Lesion no. 3 was positive for GST-P but not positive for
GGT. Lesion no. 4 was not positive for either GST-P or GGT. Bar = 1 mm
saline-Tween (PBS-T). The membrane was reacted with mouse
monoclonal anti-pan-ras antibody, clone F 11-85 (Oncogene
Science, Uniondale, NY, USA) (1:100) and then washed with PBS-
T. The membrane was reacted with horseradish peroxidase (HRP)-
labelled sheep anti-mouse IgG antibody (Amersham) (1:1500) and
washed with PBS-T. Cytosolic and membrane-associated p2lraS.
was visualized with chemiluminescence (ECL-Westem blotting
detection reagents, Amersham) followed by radiographic film
exposure. Computer-assisted image analysis was performed with
Image Master (Pharmacia Biotech, Uppsala, Sweden) to quantitate
the resulting bands.
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Figure 5 Membrane-associated p21 - in visible white nodules, serum
cholesterol levels, labelling indices and apoptotic indices of hepatic
neoplastic lesions and adjacent liver of groups 1 (sodium chloride), 2
(pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') at week 15.
Bars show s.e. Difference compared with group 1 was statistically significant:
*P < 0.05, **P < 0.01, ***P < 0.001
C-p2l
M-p21
Figure 6 Effect of pravastatin on p21 analysed by Western blotting in
groups 1 (sodium chloride, right) and 3 (pravastatin at 20 mg kg-'1 left).
C-p2l and M-p2l were cytosolic and membrane-associated isoprenylated
p21 respectively
Statistical analysis
Results were analysed using the Chi-square test, Fisher's exact
probability test or one-way analysis of variance with Dunn's
multiple comparison (Siegel, 1956; Snedecor and Cochran, 1967;
Miller, 1996). Data are shown as means ± s.e. 'Significant' indi-
cates a calculated P-value of less than 0.05.
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Figure 7 Immunohistochemical photographs of hepatic neoplastic lesions
from a control rat (A) and a rat treated with pravastatin at 20 mg kg-' body
weight (B) at week 15. Apoptosis was more frequently found in a rat treated
with pravastatin. Bar = 100 ,um
RESULTS
Body and liver weights
In week 15, no significant differences were found in the body
weight, liver weight and relative liver weight among the three
groups.
Number and size of visible white nodules and
enzyme-altered lesions
In group 1, visible white nodules were found in 16 (80%) of 20
rats, and the average number and volume of white nodules were
3.4 ± 0.3 per rat and 215 ± 28 mm3 respectively (Figure 1).
However, prolonged administration of pravastatin at doses of
10 mg kg-' (group 2) and 20 mg kg-' (group 3) significantly
reduced the incidence, number and volume of white nodules.
Microscopically, almost all of the white nodules were hepato-
cellular carcinomas.
Figure 8 Immunohistochemical photographs of hepatic neoplastic lesions
from a control rat (A) and a rat treated with pravastatin at 20 mg kg-1 body
weight (B) at week 15. Bromodeoxyuridine-labelled cells were less frequently
found in a rat treated with pravastatin. Bar = 100 gm
The two-dimensional data showed that GST-P-positive lesions
and GGT-positive lesions were significantly fewer (inhibition
18-21% for GST-P-positive lesions, 19-29% for GGT-positive
lesions) and smaller (as a percentage of the parenchyma: inhibition
26-28% for GST-P-positive lesions, 36-46% for GGT-positive
lesions) in groups 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at
20 mgkg-') than in group 1 (sodiumchloride only) (Figures 2 and 3).
Immunohistochemically, of 294 neoplastic lesions visible on
haematoxylin and eosin, 189 (64%) were positive for both GST-P
and GGT, 51 (18%) were positive for GGT but not positive for GST-
P, nine (3%) were positive for GST-P but not positive for GGT, and
45 (15%) were not positive for either GST-P or GGT (Figure 4).
Membrane-associated p21lmS labelling indices,
apoptotic indices and serum cholesterol levels
Treatment with pravastatin at 10 mg kg-' (group 2) and 20 mg kg-'
(group 3) significantly reduced the production of membrane-
associated p2lraS (inhibition 19% in group 2, 20% in group 3)
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compared with that in group 1 (Figures 5 and 6). Furthermore, rats
in groups 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at
20 mg kg-') had significantly lowerlabelling indices forneoplastic
nodules (inhibition 47% in group 2, 43% in group 3) and adjacent
hepatocytes (53% in group 2, 73% in group 3) than rats in control
group 1 (Figure 7). Pravastatin at 10 mg kg-' (group 2) and
20 mg kg-' (group 3) significantly increased the apoptotic indices
for neoplastic nodules (enhancement 165% in group 2, 190% in
group 3; Figure 8) and hepatocellularcarcinomas (269% in group 2,
335% in group 3). However, pravastatin at both dosages had no
effects on serum cholesterol levels.
DISCUSSION
The HMG-CoA reductase inhibitors are a new and novel class of
cholesterol-lowering agents that are used worldwide (Robinson et
al, 1994). However, these drugs have cytostatic effects on prolifer-
ating cells in culture (Goldstein et al, 1979; Habenicht et al, 1980;
Fairbanks et al, 1981; Maltese, 1984). Recently, Morris et al (1995)
found that lovastatin slows growth of hepatoma tissue culture-4
(HTC-4) cells at low concentrations. Lovastatin also slows cell
growth in vivo (Maltese et al, 1985). Sumi et al (1992) observed
that growth ofpancreatic carcinoma xenografts (CAV and H2T) in
nude mice is inhibited by s.c. injection of lovastatin. Kawata et al
(1992) reported that i.p. injections ofpravastatin improve survival
of AH-130 hepatoma-bearing rats and inhibits growth of ascites-
forming tumours. Moreover, Narisawa et al (1994) observed that
prolonged administration of pravastatin and simvastatin signifi-
cantly reduces the numberpermouse but notthe incidence ofcolon
tumours induced by 1,2-dimethylhydrazine in female ICR mice.
Our present results show that long-term administration of
pravastatin significantly reduces the incidence of visible white
nodules and suppresses development of enzyme-altered hepatic
lesions induced by NNM in Sprague-Dawley rats.
Although the exact mechanism by which pravastatin suppresses
hepatocarcinogenesis is still unclear, at least two possible explana-
tions can be considered. One is an inhibition of the isoprenylation
processing of ras protein (Dalton et al, 1995). The p2lras protein is
synthesized as a cytosolic precursor that is localized to the inner
plasma membrane only after it undergoes a series of post-transla-
tional modifications, including farnesylation and methylation
(Lowry and Willumsen, 1993). The activity ofp2lrLu is dependent
on its localization to the inner plasma membrane. As a conse-
quence, ras is dependent onfarnesylation to function. Confirmation
that ras requires prenylation to be active has been achieved by
blocking farnesylation, either by mutation of the CAAX box
cystein or by the treatment of cells with inhibitors of mevalonate
synthesis. In both instances, oncogenic p2lras loses the ability to
transform cells when prenylation is blocked (Cox and Der, 1992).
Kawata et al (1994) examined the effect of a combination of
pravastatin and d-limonene (an inhibitor ofprotein isoprenylation)
on cell growth ofHep G2, ahuman hepatoma-derived cell line, and
found that production of membrane-associated p21rau is decreased
to 35% of the control level. Ura et al (1994) observed that DNA
synthesis, assayed in terms of[3H]thymidine uptake, isoprenylation
ofp2lras examined with Western blotting and cell progression from
the G, to S-phase ofthe cell cycle analysed with flow cytometry in
human and hamsterpancreatic carcinoma cell lines are all inhibited
by simvastatin. In the present work, we found that prolonged
administration of pravastatin causes a significant decrease in
membrane-associated p21r- in visible white nodules.
A second possibility is the inhibition ofother pathways affected
by pravastatin, such as cholesterol biosynthesis (Buchwald, 1992).
DeClue et al (1991) observed that inhibition ofcell growth in vitro
by lovastatin was not specific for cells whose transformation is
dependent upon isoprenylated ras protein and suggested that other
pathways are responsible for the growth inhibition by lovastatin.
Sumi et al (1991) found that lovastatin inhibits cell growth of the
human pancreatic cell line CAV by 78%, but the CAV cell line
does not have a mutation in either H- or N-ras genes. They
concluded that lovastatin's inhibition of pancreatic cell growth is
not directly dependent on the presence of the ras mutation.
Moreover, Herold et al (1995) observed that lovastatin markedly
and dose-dependently inhibits proliferation ofcultured enterocytes
(CaCo-2), and that this suppression was reversed by the addition
ofeither exogenous free cholesterol, endogenous cholesterol from
mevalonolactone, orlow-density lipoproteins. In the present study,
however, we found that pravastatin at both dosages had no effects
on serum cholesterol levels.
The ratio of labelling index of the neoplastic nodules to that of
the adjacent liver was 4, 4.6 and 8.5 for groups 1 (sodium
chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at
20 mg kg-') respectively (Figure 5). This suggests that pravastatin
had stronger effects on adjacent hepatocytes than on enzyme-
altered lesions. However, its mechanism remains unclear.
Our present results show that administration of pravastatin
suppresses hepatocarcinogenesis induced by NNM in rats and also
significantly reduces amounts of membrane-associated p2lraS.
These findings suggest that the suppression of hepatocarcino-
genesis by pravastatin might be related to its inhibition of p2lras
isoprenylation and its subsequent inhibition of cell proliferation
and induction ofapoptosis in neoplastic lesions.
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